Management of Myelodysplastic Syndromes: Emerging Therapies and Evidence-Based Practice
Journal of the Advanced Practitioner in Oncology · 27.02.2026 · 17 (2)
DOI: 10.6004/jadpro.2026.17.2.13 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 27.02.2026. Verfasst von Kathryn E. Kennedy und 8 weiteren Autor:innen.
Themen: Evidenzbasierte Pflege
Abstract (Originalsprache)
At JADPRO Live 2025, speakers discussed the latest safety and efficacy evidence behind recently approved therapies for myelodysplastic syndromes, implementing adverse event monitoring and management plans to support adherence and patient safety, and integrating current evidence into treatment decisions to reduce transfusion dependence and improve quality of life for patients with MDS.
Zitieren
APA
Kennedy, K. E., MSN, APRN, ACNP-BC, AOCN, West, O. C., MSN, RN, & AGACNP-BC (2026). Management of Myelodysplastic Syndromes: Emerging Therapies and Evidence-Based Practice. Journal of the Advanced Practitioner in Oncology, 17(2). https://doi.org/10.6004/jadpro.2026.17.2.13
Vancouver
Kennedy KE, MSN, APRN, ACNP-BC, AOCN, West OC, et al. Management of Myelodysplastic Syndromes: Emerging Therapies and Evidence-Based Practice. Journal of the Advanced Practitioner in Oncology. 2026;17(2). doi:10.6004/jadpro.2026.17.2.13
BibTeX
@article{Kennedy2026,
author = {Kennedy, Kathryn E. and MSN and APRN and ACNP-BC and AOCN and West, Olivia C. and MSN and RN and AGACNP-BC},
title = {Management of Myelodysplastic Syndromes: Emerging Therapies and Evidence-Based Practice},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {2},
doi = {10.6004/jadpro.2026.17.2.13}
}
EUVIMED